CClinicalTrials.gg
CompletedNCT05552417Updated May 23, 2024

Pectointercostal Block for Postoperative Pain Management After Sternotomy

An interventional study of Pectointercostal facial plan block in Post Operative Pain, sponsored by Kasr El Aini Hospital. Completed at 1 site in Egypt. Open to participants aged 6 Months to 36 Months. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by Kasr El Aini Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
6 Months to 36 Months
Sex
All
01

Study summary

This randomized, controlled study is designed to assess the quality of analgesia provided by ultrasound-guided bilateral pectointercostal facial block in children undergoing cardiac surgery via midline sternotomy.

Read the detailed description

Following approval from the research and ethics committee ,preoprrative preparation, and induction of anesthesia The patient will be assigned to two equal groups. Conventional control group(C) (n=30) where --- children will not receive any intervention.

Pectointercostal facial group (PI) (n=30) where --children will have bilateral Pectointercostal Block.

Patient positioning and preparation for Ultrasound-guided PIFB After skin disinfection, the PIFB will be performed in a supine position using a high-frequency (6-13 MHz) linear ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA). The probe will be placed at 2 cm lateral from the sternum and parallel to the sternum and will be scanned laterally to identify 4th and 5th costal cartilage The pecto-intercostal fascial plane will be located between the pectoralis major muscle and the external intercostal muscle or the costal cartilage. A 22G, 50 mm peripheral block needle, Stimuplex® Ultra 360 (B. Braun, Melsungen, Germany) will be placed under the pectoralis major and above the external intercostal muscle with an in-plane approach with the ultrasound probe, in a caudal-to-cranial direction until the tip is positioned in the interfascial plane between the PMM and IIM .

A test bolus of saline (1 mL) will be injected to determine that the tip has been placed in the correct fascial layers. Finally, 1.5 mg/kg of 0.2% bupivacaine will be injected into this plane in two locations, over the 2nd and 4th rib. The method on the other side of the PIFB will be the same Care will be taken not to cross the toxic dose of bupivacaine (3 mg/kg). (6) .

Heart rate, mean arterial pressure, and oxygen saturation will be monitored continuously.

After completion of the surgery, inhalational anesthetics will be stopped as well as the muscle relaxant.

The patient will be then transferred to the ICU.Postoperative assessment and analgesic regimen: An IV Paracetamol 15 mg / kg will be given and will be repeated every 8 hours .The Face, Legs, Activity, Cry, Consolability scale (FLACC) (table 1) will be assessed in the PICU and every 4 hours for 24 hours. The time to the first request of rescue postoperative analgesic will be: "the time interval between the onset of block and the first request to postoperative analgesia". When patients first complain of pain (FLACC score ≥4) rescue analgesia will be given in the form of incremental intravenous morphine

02

Conditions studied

  • Post Operative Pain

Browse trials for

03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Kasr El Aini Hospital is the lead sponsor of 273 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • age 6 to 36 months
  • sex both
  • Weight > 5kg
  • Pathology A-V canal , ASD closure, VSD closure surgery through a midline sternotomy.

Exclusion criteria

Exclusion Criteria:

  • Redo patient.
  • History of allergic reactions to local anesthetics.
  • Bleeding disorders with INR > 1.5 and/or platelets \< 50 000.
  • Rash or signs of infection at the injection site.
  • Emergency procedures.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • No intervention
    control group

    Conventional control group(C) (n=--) where --- children will not receive any intervention.

  • Active comparator
    Pectointercostal

    Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.

    Other: Pectointercostal facial plan block

Interventions

  • OtherPectointercostal facial plan block

    Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.

    Also known as: Pectointercostal facial nerve block

06

What researchers measure

Primary outcomes

  1. Post-operative pain score

    Post-operative pain score by The Face, Legs, Activity, Cry, Consolability scale ( Each category is scored on a 0-2 scale, which results in a total score of 0-10 0:comfortable,1-3:Mild discomfort,4-6:Moderate discomfort, \&7-10:Sever discomfort ) (FLACC) scale pain score at 4 hours.

    Time frame: At 4 hours.

07

Study locations

1 site
  • Kasralainy Faculty of Medicine
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05552417
Lead sponsor
Kasr El Aini Hospital
Responsible party
Ahmed Mohamed Mohamed Elhaddad (Lecturer of Anesthesia, ICU and Pain managment, Kasr El Aini Hospital) — Principal investigator
First posted
Sep 23, 2022
Start date
Mar 1, 2023
Primary completion
Jan 1, 2024
Completion
Mar 1, 2024
Last update
May 23, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion